Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + vandetanib
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Bevacizumab + vandetanib is an investigational combination therapy consisting of two targeted agents used in oncology. Bevacizumab is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis. Vandetanib is a small molecule tyrosine kinase inhibitor with activity against VEGF receptor 2 (VEGFR2), epidermal growth factor receptor (EGFR), and RET receptor. The rationale for combining these drugs is to achieve dual blockade of the VEGF pathway and inhibit tumor angiogenesis more effectively than either agent alone. This combination has been evaluated in phase I clinical trials for patients with advanced solid tumors and lymphomas, demonstrating preliminary evidence of anti-tumor activity and manageable toxicity profiles[1][2].
02
Targets
EGFR (Epidermal growth factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on bevacizumab + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + vandetanib.